CEL-SCI Corp (CVM)

1.65
0.05 3.12
AMEX : Health Care
Prev Close 1.60
Open 1.60
Day Low/High 1.60 / 1.69
52 Wk Low/High 0.36 / 0.80
Volume 101.81K
Avg Volume 200.50K
Exchange AMEX
Shares Outstanding 10.08M
Market Cap 16.13M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI To Present At The 19th Annual Rodman & Renshaw Global Investment Conference On September 11, 2017

CEL-SCI To Present At The 19th Annual Rodman & Renshaw Global Investment Conference On September 11, 2017

CEL-SCI Corporation (NYSE American: CVM), today announced Geert Kersten, Chief Executive Officer, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to December 1, 2017 (close of business).

CEL-SCI Announces $3.5 Million Registered Direct Offering

CEL-SCI Announces $3.5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE American:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $3.

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

U.S. FDA Removes Clinical Hold On CEL-SCI's Phase 3 Head & Neck Cancer Trial

U.S. FDA Removes Clinical Hold On CEL-SCI's Phase 3 Head & Neck Cancer Trial

CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from August 10, 2017 to September 10, 2017 (close of business).

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2017.

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Corporation (NYSE MKT:CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from July 10, 2017 to August 10, 2017 (close of business).

CEL-SCI Announces Reverse Stock Split

CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.

CEL-SCI Announces New Data For Its Rheumatoid Arthritis Vaccine Candidate Published In Peer Reviewed Journal

CEL-SCI Corporation (NYSE MKT: CVM) announces the publication of data from rheumatoid arthritis (RA) studies in Vaccine, a leading peer-reviewed journal for researchers interested in vaccines and vaccination.

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Corporation (NYSE MKT: CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from June 8, 2017 to July 10, 2017 (close of business).

CEL-SCI Submits FDA Response For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has responded to the U.

CEL-SCI Corporation Releases Letter To Shareholders

The following letter is being released by CEL-SCI Corporation (NYSE MKT:CVM) to its shareholders: Dear Fellow Shareholders: We are giving you an update on clinical hold communications with the U.

CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Daniel Zimmerman, Ph.

CEL-SCI Announces Change To The Date Of Its Annual Meeting

CEL-SCI Corporation (NYSE MKT: CVM) today announced it has changed the date for its annual meeting from June 9, 2017 to June 12, 2017.

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2017.

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.

CEL-SCI Announces $1.51 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with one institutional investor for an offering of shares of common stock with gross proceeds of approximately $1.

CEL-SCI Receives Intent To Grant Notice For New Multikine Patent From The European Patent Office

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has been notified that it will be granted a new patent on Multikine* (Leukocyte Interleukin, Injection), its investigational cancer immunotherapy, from the...

CEL-SCI Corporation Releases Letter To Shareholders

The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders: Dear Fellow Shareholders: Our Phase 3 study in advanced primary (untreated) head and neck cancer...

CEL-SCI Scientist Presents At The World Vaccine Congress

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Dr.

CEL-SCI Announces $1.5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $1.

CEL-SCI Gives Update On Partial Clinical Hold On Phase 3 Head And Neck Cancer Study With Multikine

CEL-SCI Corporation (NYSE MKT: CVM) announces that it has received the official minutes from its February 8, 2017 meeting with the U.

CEL-SCI Announces That The NYSE MKT Approves Plan

CEL-SCI Corporation (NYSE MKT: CVM) announces that the NYSE MKT (the "Exchange") has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.

CEL-SCI Scientist Presents New Findings For Rheumatoid Arthritis Treatment Vaccine At Conference

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Dr.

CEL-SCI Announces $1.0 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $1.

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2016.

TheStreet Quant Rating: E+ (Sell)